| Not Yet Recruiting | Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma NCT07379489 | Tongji Hospital | — |
| Not Yet Recruiting | PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0) NCT07267234 | Second Affiliated Hospital of Soochow University | Phase 2 |
| Active Not Recruiting | Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable NCT07339488 | Chuangzhen Chen | Phase 2 |
| Not Yet Recruiting | Study on the Relationship Between Opioid Drugs and the Therapeutic Efficacy of Immunotherapy NCT07188857 | Hubei Cancer Hospital | — |
| Recruiting | Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC NCT07186621 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 |
| Recruiting | Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors NCT07058948 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic NCT06227728 | Gene Solutions | — |
| Unknown | Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or NCT05910970 | Guangxi Medical University | Phase 3 |
| Recruiting | Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer NCT06197581 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | N/A |
| Recruiting | IC Plus Low-dose Radiation Plus Cadonilimab in LANPC NCT05941741 | Sun Yat-sen University | Phase 3 |
| Recruiting | A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy NCT06255223 | Jinling Hospital, China | Phase 2 |
| Recruiting | COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research NCT06168032 | Peking Union Medical College Hospital | N/A |
| Not Yet Recruiting | A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point NCT06142617 | Peking Union Medical College Hospital | Phase 2 |
| Completed | A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant NCT05848011 | MacroGenics | Phase 2 |
| Recruiting | Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC NCT05754203 | Xinqiao Hospital of Chongqing | N/A |
| Completed | Troponin to Detect Major Cardiovasculaire Advserse Events on Immune Checkpoint Inhibitors NCT06007274 | Institut Mutualiste Montsouris | — |
| Recruiting | Liver Cancer and Immunotherapy in the Liquid Biopsy Era NCT05810402 | University Hospital, Montpellier | N/A |
| Unknown | Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors NCT05915481 | Peking University Third Hospital | Phase 1 / Phase 2 |
| Unknown | Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection NCT05913583 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Unknown | Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer NCT05982301 | Fudan University | Phase 2 |
| Not Yet Recruiting | A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC NCT05698264 | Nir Peled | N/A |
| Recruiting | LAG3 Expression in Triple Negative Breast Cancer NCT06259162 | Samsung Medical Center | N/A |
| Withdrawn | Clinical Significance of Hepatic Biomarkers in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors NCT05653531 | Centre Hospitalier Universitaire, Amiens | N/A |
| Unknown | Development of an EORTC Immune Checkpoint Inhibitor-specific Quality of Life Item List: Phase 1 & 2 NCT05554432 | Institut Curie | — |
| Unknown | Safety and Efficacy of RX-af01 Combined With PD-1 Antibody NCT05576961 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Active Not Recruiting | Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy NCT05383716 | Peking Union Medical College Hospital | Phase 2 |
| Unknown | Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Ca NCT05385185 | Hebei Medical University | Phase 2 |
| Unknown | PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer NCT05311566 | Lei Li | Phase 2 |
| Recruiting | Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors NCT05799898 | Institut Mutualiste Montsouris | — |
| Unknown | Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy NCT06074029 | Peking Union Medical College Hospital | Phase 1 / Phase 2 |
| Recruiting | Toripalimab Plus FLOT in Locally Advanced Gastric Cancer NCT04891016 | Henan Cancer Hospital | Phase 2 |
| Unknown | Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC NCT04867330 | Fudan University | N/A |
| Unknown | Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer NCT05863260 | Fudan University | — |
| Unknown | Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atez NCT04659382 | Federation Francophone de Cancerologie Digestive | Phase 2 |
| Unknown | Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC Patients NCT04473703 | Shanghai Chest Hospital | — |
| Unknown | Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma NCT04414969 | Hunan Cancer Hospital | Phase 2 |
| Unknown | Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma NCT04419441 | Ospedale Maggiore Di Trieste | — |
| Completed | Thyroid Dysfunction and Nivolumab Reponse in NSCLC NCT04470440 | University Hospital, Brest | — |
| Completed | Immune Checkpoint Inhibitors(ICPis)-Induced Endocrine Immune-related Adverse Events (irAEs) NCT05675111 | Nanjing Medical University | — |